Aderbasib

Aderbasib
Clinical data
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name methyl (6S,7S)-7-(hydroxycarbamoyl)-6-[(4-phenyl-1-piperazinyl)carbonyl]-5-azaspiro[2.5]octane-5-carboxylate;
CAS Number	791828-58-5;
PubChem CID	[https://pubchem.ncbi.nlm.nih.gov/compound/16070111 Q03790 16070111 Q03790];
ChemSpider	17229620;
UNII	V9YL6NEJ3G;
KEGG	[https://www.kegg.jp/entry/D09320 Q03790 D09320 Q03790];
ChEMBL	ChEMBL2103790;
CompTox Dashboard (EPA)	DTXSID701000327 ;
Chemical and physical data
Formula	C21H28N4O5
Molar mass	416.478 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC(=O)N1CC2(CC2)C[C@@H]([C@H]1C(=O)N3CCN(CC3)C4=CC=CC=C4)C(=O)NO;
	InChI InChI=1S/C21H28N4O5/c1-30-20(28)25-14-21(7-8-21)13-16(18(26)22-29)17(25)19(27)24-11-9-23(10-12-24)15-5-3-2-4-6-15/h2-6,16-17,29H,7-14H2,1H3,(H,22,26)/t16-,17-/m0/s1; Key:DJXMSZSZEIKLQZ-IRXDYDNUSA-N;

Aderbasib (codenamed INCB7839) is a sheddase inhibitor that may suppress tumor cell proliferation.^[1] Acting on multiple receptor classes and subclasses, aderbasib is observed to regulate the tumor necrosis factor of cancer cells.^[2] Aderbasib was being developed by Incyte as a potential adjunctive treatment for metastatic breast cancer. Development was halted in 2011 after positive findings from Phase II trials were contradicted by further research.^[3]^[4]

More specifically, aderbasib is an inhibitor of ADAM10 and ADAM17.^[5]

References

^ "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.
^ "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.
^ Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.
^ "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.
^ Yang L, Bhattacharya A, Li Y, Sexton S, Ling X, Li F, et al. (June 2022). "Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer". Journal of Experimental & Clinical Cancer Research. 41 (1): 184. doi:10.1186/s13046-022-02389-z. PMC 9161494. PMID 35650607.

External links

NCI Thesaurus

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[1] "STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL" (PDF). Ama-assn.org. Retrieved 2012-10-13.

[2] "Aderbasib | CAS#791828-58-5". MedKoo. Retrieved 2012-10-13.

[3] Incyte (2011-09-19). "UBS 2011 Global Life Sciences Conference". Retrieved 2013-02-13.

[4] "Incyte Reports Third Quarter 2011 Financial Results And Provides Update On Key Clinical Programs" (Press release). BusinessWire. 2011-10-27. Retrieved 2013-02-13.

[pmid35650607-5] Yang L, Bhattacharya A, Li Y, Sexton S, Ling X, Li F, et al. (June 2022). "Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer". Journal of Experimental & Clinical Cancer Research. 41 (1): 184. doi:10.1186/s13046-022-02389-z. PMC 9161494. PMID 35650607.

[1]

[2]

[3]

[4]

[5]